492 related articles for article (PubMed ID: 26900075)
1. The challenges associated with molecular targeted therapies for glioblastoma.
Jue TR; McDonald KL
J Neurooncol; 2016 May; 127(3):427-34. PubMed ID: 26900075
[TBL] [Abstract][Full Text] [Related]
2. Molecular pathways and potential therapeutic targets in glioblastoma multiforme.
Wardak Z; Choe KS
Expert Rev Anticancer Ther; 2013 Nov; 13(11):1307-18. PubMed ID: 24168050
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date.
Bastien JI; McNeill KA; Fine HA
Cancer; 2015 Feb; 121(4):502-16. PubMed ID: 25250735
[TBL] [Abstract][Full Text] [Related]
4. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
5. Translational validation of personalized treatment strategy based on genetic characteristics of glioblastoma.
Oh YT; Cho HJ; Kim J; Lee JH; Rho K; Seo YJ; Choi YS; Jung HJ; Song HS; Kong DS; Seol HJ; Lee JI; Yoon Y; Kim S; Nam DH; Joo KM
PLoS One; 2014; 9(8):e103327. PubMed ID: 25084005
[TBL] [Abstract][Full Text] [Related]
6. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
7. Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma.
Ferri A; Stagni V; Barilà D
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664581
[TBL] [Abstract][Full Text] [Related]
8. Glioblastoma targeted therapy: updated approaches from recent biological insights.
Touat M; Idbaih A; Sanson M; Ligon KL
Ann Oncol; 2017 Jul; 28(7):1457-1472. PubMed ID: 28863449
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma.
Qazi MA; Vora P; Venugopal C; Sidhu SS; Moffat J; Swanton C; Singh SK
Ann Oncol; 2017 Jul; 28(7):1448-1456. PubMed ID: 28407030
[TBL] [Abstract][Full Text] [Related]
10. Toward precision medicine in glioblastoma: the promise and the challenges.
Prados MD; Byron SA; Tran NL; Phillips JJ; Molinaro AM; Ligon KL; Wen PY; Kuhn JG; Mellinghoff IK; de Groot JF; Colman H; Cloughesy TF; Chang SM; Ryken TC; Tembe WD; Kiefer JA; Berens ME; Craig DW; Carpten JD; Trent JM
Neuro Oncol; 2015 Aug; 17(8):1051-63. PubMed ID: 25934816
[TBL] [Abstract][Full Text] [Related]
11. A Thermodynamic-Based Interpretation of Protein Expression Heterogeneity in Different Glioblastoma Multiforme Tumors Identifies Tumor-Specific Unbalanced Processes.
Kravchenko-Balasha N; Johnson H; White FM; Heath JR; Levine RD
J Phys Chem B; 2016 Jul; 120(26):5990-7. PubMed ID: 27035264
[TBL] [Abstract][Full Text] [Related]
12. Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies.
Agnihotri S; Burrell KE; Wolf A; Jalali S; Hawkins C; Rutka JT; Zadeh G
Arch Immunol Ther Exp (Warsz); 2013 Feb; 61(1):25-41. PubMed ID: 23224339
[TBL] [Abstract][Full Text] [Related]
13. Using the molecular classification of glioblastoma to inform personalized treatment.
Olar A; Aldape KD
J Pathol; 2014 Jan; 232(2):165-77. PubMed ID: 24114756
[TBL] [Abstract][Full Text] [Related]
14. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
15. Emerging therapeutic targets and agents for glioblastoma migrating cells.
Di C; Mattox AK; Harward S; Adamson C
Anticancer Agents Med Chem; 2010 Sep; 10(7):543-55. PubMed ID: 20950259
[TBL] [Abstract][Full Text] [Related]
16. Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets.
Mao H; Lebrun DG; Yang J; Zhu VF; Li M
Cancer Invest; 2012 Jan; 30(1):48-56. PubMed ID: 22236189
[TBL] [Abstract][Full Text] [Related]
17. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
Daher A; de Groot J
Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
[TBL] [Abstract][Full Text] [Related]
18. Surfaceome Proteomic of Glioblastoma Revealed Potential Targets for Immunotherapy.
Rose M; Cardon T; Aboulouard S; Hajjaji N; Kobeissy F; Duhamel M; Fournier I; Salzet M
Front Immunol; 2021; 12():746168. PubMed ID: 34646273
[TBL] [Abstract][Full Text] [Related]
19. Current Development of Glioblastoma Therapeutic Agents.
Wang Z; Peet NP; Zhang P; Jiang Y; Rong L
Mol Cancer Ther; 2021 Sep; 20(9):1521-1532. PubMed ID: 34172531
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents.
Reardon DA; Wen PY
Oncologist; 2006 Feb; 11(2):152-64. PubMed ID: 16476836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
